Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
511 results
Cited 40 times since 1984 (1 per year) source: EuropePMC
Cancer treatment reports, Volume 68, Issue 12, 1 1 1984, Pages 1471-1474 High-dose etoposide for refractory malignancies: a phase I study. Postmus PE, Mulder NH, Sleijfer DT, Meinesz AF, Vriesendorp R, de Vries EG
Etoposide is active against a number of solid tumors when used in a standard dose. The toxicity at a standard dose level is mild myelosuppression without extramedullary toxicity. Recent studies in man support the dose-response relationship of etoposide. In a group of 22 patients with progressive disseminated malignancies, the dose of etoposide was escalated to define dose-limiting extramedullary toxicity, which was oropharyngeal mucositis at a dose level of 3.5 g/m2. Bone marrow toxicity was com... Abstract
Cited 5 times since 1984 (0.1 per year) source: EuropePMC
Blut, Volume 49, Issue 5, 1 1 1984, Pages 419-421 No narcosis for bone marrow harvest in autologous bone marrow transplantation. de Vries EG, Vriesendorp R, Meinesz AF, Mulder NH, Postmus PE, Sleijfer DT
A prospective study with mild general analgesia and sedation together with local anesthesia during bone marrow harvest was performed. Thirty-one patients underwent 33 bone marrow collections. Pretreatment consisted of 100 mg meperidine i.m. and 20 mg diazepam i.m. 1 h before start of procedure. Eight patients got additional meperidine and diazepam during the procedure, all patients got lidocaine 1% locally. A mean volume of 1.321 was obtained with 42.5 punctures. Twenty-two patients had no compl... Abstract
Cited 5 times since 1984 (0.1 per year) source: EuropePMC
Annals of internal medicine, Volume 101, Issue 5, 1 1 1984, Pages 717 Remission of brain metastases from small-cell lung cancer after high-dose chemotherapy. Postmus PE, Haaxma-Reiche H, Vencken LM, Meinesz AF, Sleijfer DT, Mulder NH
Cited 17 times since 1984 (0.4 per year) source: EuropePMC
European journal of cancer & clinical oncology, Volume 20, Issue 6, 1 1 1984, Pages 777-782 Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study. Postmus PE, de Vries EG, De Vries-Hospers HG, Vriesendorp R, van Imhoff GW, Holthuis JJ, Sibinga CT, Sleijfer DT, Mulder NH
In 13 patients with therapy-resistant solid tumors the feasibility of high-dose cyclophosphamide (7 g/m2) in combination with increasing doses of VP 16-213 with autologous bone marrow transplantation was studied. Dose-limiting extramedullary toxicity appeared to be mucositis and occurred after 2.5 g/m2. Two toxic deaths were observed in patients older than 55 yr. Responses were seen in eight out of nine evaluable patients. Two patients with ovarian cancer still have no signs of disease progressi... Abstract
Cited 13 times since 1984 (0.3 per year) source: EuropePMC
Gynecologic oncology, Volume 17, Issue 3, 1 1 1984, Pages 271-276 Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. Vriesendorp R, Aalders JG, Sleijfer DT, Postmus PE, Willemse PH, Bouma J, Mulder NH
Two patients with persistent minimal ovarian cancer after conventional polychemotherapy were treated with high doses of cyclophosphamide and VP 16-213 followed by autologous bone marrow infusion. Ten months afterward no clinical signs of tumor were apparent. In one patient the complete response was surgically documented. Toxicity included cardiac and pulmonary arrest during marrow infusion in one patient, but was otherwise manageable. This method of late intensification of chemotherapy in patien... Abstract
Cited 45 times since 1984 (1.1 per year) source: EuropePMC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 2, Issue 3, 1 1 1984, Pages 215-220 Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. Postmus PE, Holthuis JJ, Haaxma-Reiche H, Mulder NH, Vencken LM, van Oort WJ, Sleijfer DT, Sluiter HJ
VP 16-213 in standard doses is active against a number of solid tumors. Its penetration into the cerebrospinal fluid (CSF) is very limited at these dose levels. In 10 patients treated with high-dose VP 16-213 (0.9-2.5 g/m2), CSF levels of up to 0.54 microgram/mL were detected. In two patients with central nervous system (CNS) metastases of small cell lung cancer (SCLC) a response was seen after 1.0 and 1.5 g/m2 intravenously. High-dose VP 16-213 can possibly play a role in the treatment of CNS m... Abstract
Cited 4 times since 1984 (0.1 per year) source: EuropePMC
Cancer, Volume 53, Issue 3, 1 1 1984, Pages 396-400 Small cell lung cancer and the influence of chemotherapy on CFUcs in bone marrow. Postmus PE, Mulder NH, de Vries EG, van Luyn M, Halie MR
To determine the optimal moment for the harvesting of bone marrow for autologous transplantation, the authors did serially colony forming units in culture (CFUc) counts in a group of 42 patients with small cell lung cancer (SCLC) before and after remission induction chemotherapy and subsequent maintenance chemotherapy. Disease stage did not influence the CFUc count except in patients with bone marrow metastases; this resulted in either abnormally low or abnormally high CFUc counts, probably depe... Abstract
Cited 4 times since 1984 (0.1 per year) source: EuropePMC
The Netherlands journal of medicine, Volume 27, Issue 10, 1 1 1984, Pages 389-392 Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT). Mulder NH, Meinesz AF, Sleijfer DT, Postmus PE, De Vries EG, Van der Geest S, Orie JL, Vriesendorp R
Cited 6 times since 1983 (0.1 per year) source: EuropePMC
Blut, Volume 47, Issue 4, 1 1 1983, Pages 203-209 Autologous cryopreserved platelets and prophylaxis of bleeding in autologous bone marrow transplantation. van Imhoff GW, Arnaud F, Postmus PE, Mulder NH, Das PC, Smit Sibinga CT
Autologous platelets were harvested and cryopreserved in eight consecutive patients elected for ablative chemotherapy and autologous bone marrow transplantation (ABMT) for solid malignancy. There was a 19% loss in platelet count after the freeze thaw and wash procedure; with an in vitro functional loss of 40-60%. No correlation could be found for individual platelet transfusions between in vitro functional tests and in vivo recovery. Six consecutive patients received a total of 16 autologous pla... Abstract
Cited 13 times since 1983 (0.3 per year) source: EuropePMC
Cancer treatment reports, Volume 67, Issue 1, 1 1 1983, Pages 21-26 Complications of treatment of small cell carcinoma of the lung. Abeloff MD, Klastersky J, Drings PD, Eagan RT, Greco FA, Holsti L, Mattson K, Postmus PE
Improvements in therapy for small cell carcinoma of the lung have been achieved with treatment regimens that result in significant toxicity. The workshop of the International Association for the Study of Lung Cancer focused on the following complications of chemotherapy and radiotherapy: leukopenia and resultant infections, esophagitis, pneumonitis and pulmonary fibrosis, cardiac toxicity, second malignancies, neurologic complications, and psychosocial effects. The data regarding the incidence a... Abstract
Nederlands tijdschrift voor geneeskunde, Volume 126, Issue 20, 1 1 1982, Pages 906-913 [The treatment of patients with lung carcinoma]. van der Wal AM, Elema JD, Jansen HM, Luursema PB, Postmus PE, Sleyfer DT, Vermey J